secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093936
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q2 2024 cash $137.2M; revenue $25.1M; CX-904 update expected by year-end
-------------------------------------------------------------------------------

- Cash, equivalents and investments $137.2M at June 30, 2024, down from $150.3M at March 31, 2024.
- Total revenue $25.1M in Q2 2024, up from $24.7M in Q2 2023; R&D expense $25.2M incl. $5M milestone to AbbVie.
- CX-904 (EGFRxCD3) Phase 1a enrollment continues in PDAC, NSCLC, HNSCC; program update expected by end of 2024.
- CX-2051 (EpCAM ADC) Phase 1 dose escalation in third cohort; initial data expected in first half of 2025.
- CX-801 (IFNα2b cytokine) first clinical site active; initial data expected in 2025; $10M Astellas milestones achieved YTD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017024093936/0000950170-24-093936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017024093936/ctmx-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer